Ignite Creation Date:
2024-05-05 @ 10:30 PM
Last Modification Date:
2024-10-26 @ 10:19 AM
Study NCT ID:
NCT01123811
Status:
COMPLETED
Last Update Posted:
2010-05-14
First Post:
2010-05-07
Brief Title:
Efficacy of Cetuximab in Combination With Irinotecan and 5- FUFA in Treatment of Metastatic Gastric Cancer
Sponsor:
Johannes Gutenberg University Mainz
Organization:
Johannes Gutenberg University Mainz
Study Overview
Official Title:
An Open-label Non-randomized Phase II Trial of Cetuximab in Combination With Irinotecan and 5-FUFA for Patients With Metastatic Gastric Cancer
Status:
COMPLETED
Status Verified Date:
2006-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
GC-CIF-2005
Brief Summary:
Based on the current promising results with irinotecan and cetuximab in patients with recurrent metastatic colorectal cancer and the excellent results of Irinotecan and 5-FU in gastric cancer the present clinical study to evaluate the overall response rate the time to progression and the overall survival of the combined treatment of cetuximab and irinotecan and 5-FU in patients with esophagogastric cancer is urgently needed
Detailed Description:
Cetuximab will be analysed with biological markers
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None